Cardiff Oncology Inc.

04/12/2021 | Press release | Distributed by Public on 04/12/2021 04:05

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC